🇺🇸

US SEC Filing Intelligence

· daily

NME Blockbuster Approvals — June 23, 2026

This period's FDA digest covers a single NME approval, TEBIPENEM, PIVOXIL (UTEBZI) from GLAXOSMITHKLINE LLC, which received Priority Review and is classified as a FALLBACK approval type. The approval is assessed as bullish with high confidence, reflecting the unmet need addressed by this new oral antibiotic. No biosimilar or label expansion approvals were recorded, limiting broader sector signals. The highest-conviction signal is the NME approval itself, which strengthens GSK's pipeline credibility in infectious disease. Key risks include the lack of disclosed commercial data (peak sales, pricing, exclusivity) and the FALLBACK designation, which may imply a narrower indication or conditional approval.

1 total filings
· daily

Big Pharma Approvals — June 23, 2026

This single-approval period features GlaxoSmithKline's NME tebipenem pivoxil (UTEBZI), a Priority Review oral carbapenem antibiotic for complicated urinary tract infections. The approval is classified as a 'fallback' type, suggesting it may serve as a second-line or reserved therapy, which tempers the commercial upside relative to a first-line NME launch. Despite the bullish signal (8/10 strength, 8/10 materiality), the lack of disclosed peak sales estimates, exclusivity duration, or pricing power leaves significant uncertainty around revenue potential. The dominant therapeutic area theme is anti-infectives, but with only one approval, no sector-wide clustering is evident. The key risk is the absence of commercial detail and the fallback designation, which could limit market penetration versus existing oral and IV alternatives.

1 total filings
· daily

New Drug Approvals (Original) — June 23, 2026

During the period of June 23, 2026 to June 23, 2026, the FDA issued 10 approvals, all classified as 'Other' (FALLBACK), with zero NMEs, zero biosimilars, and zero label expansions. The dominant theme is a wave of generic/biosimilar-like approvals for established molecules, with two exceptions flagged as bullish: GSK's NME TEBIPENEM PIVOXIL (UTEBZI) received Priority Review, representing a high-conviction signal for a novel oral antibiotic, and AZURITY's label expansion for APREPITANT. The highest-conviction signal is GSK's TEBIPENEM PIVOXIL approval, which, as a new molecular entity with Priority Review, signals a potential commercial opportunity in the anti-infective space. Key risks include the lack of disclosed commercial data for all approvals, making peak sales and pricing power assessments impossible, and the neutral-to-low materiality of the 8 remaining approvals which are largely generic entries.

10 total filings
· daily

DHS Homeland Security Contracts — June 23, 2026

The single contract analyzed, a $138.3 million firm-fixed-price delivery order from the Transportation Security Administration (TSA) to Analogic Corp, signals a long-term, competitive win in the civilian airport security detection market. The contract, which has a potential value of $499.7 million including options through 2033, is fully civilian (0% defense-related) and reflects sustained TSA investment in advanced computed tomography (CT) technology. The highest-conviction signal is the competitive nature of the award—full and open competition with no set-aside—indicating Analogic's technological edge over rivals. A key risk is the firm-fixed-price structure, which places execution and cost-overrun risk on Analogic, and the medium contract risk rating suggests careful monitoring of margin performance is warranted.

1 total filings
· daily

HHS & Healthcare Contracts Intelligence — June 23, 2026

The June 23, 2026 HHS contracts digest totals $262.8 million in obligations, split entirely between two civilian-sector awards from HHS agencies (BARDA and NIH/NCI). The largest contract is a $141.3 million biotechnology R&D award to START2 GROUP, INC., an early-stage small disadvantaged business, raising execution risk given only $2.8 million outlayed to date. Leidos Biomedical Research’s $121.5 million cost-plus-fixed-fee award provides stable, low-risk revenue through August 2024, but with modest profit upside. The dominant sector theme is sustained federal health R&D investment, though both contracts exhibit neutral signals with no clear bullish catalysts, while START2 GROUP’s performance milestone risk is a key watch item for investors tracking small-cap government services exposure.

2 total filings
· daily

New Federal Contractors — June 23, 2026

The three contracts awarded between June 23, 2026, and June 23, 2026, total $401.1 million, with one-third defense-related and an average signal strength of 5.7/10. The dominant theme is civilian health and security spending, led by HHS ($262.8M combined across START2 GROUP and Leidos Biomedical) and DHS/TSA ($138.3M to Analogic Corp). Highest-conviction signal is the bullish, competitive win by Analogic Corp for $138.3M in TSA CT systems, offering long-term revenue visibility through 2033. Key risk is execution and scalability for START2 GROUP, a small, foreign-owned disadvantaged business with only $2.8M outlayed on a $141.3M BARDA contract, presenting high pricing risk and early-stage funding gaps.

3 total filings
· daily

Significant Contract Modifications ($10M+) — June 23, 2026

The three contracts analyzed total $401.1 million in obligations, with a civilian-heavy split (2/3 HHS, 1/3 DHS) and no direct DoD awards. The dominant theme is federal investment in advanced health R&D and airport security technology, with BARDA (HHS) and TSA (DHS) as key agencies. The highest-conviction signal is the bullish $138.3 million TSA CT system award to Analogic Corp, reflecting competitive strength and long-term revenue visibility through 2033. Key risks include the early-stage, high-execution-risk $141.3 million BARDA contract to START2 GROUP, INC., which has only $2.8 million outlayed, and the upcoming August 2024 expiration of Leidos Biomedical Research's $121.5 million NIH contract, which creates re-compete uncertainty.

3 total filings
· daily

Contract Deobligations Alert — June 23, 2026

This digest covers $401.1 million in total obligations across three contracts, with a 2:1 civilian-to-defense split (HHS and DHS vs. no pure DOD awards). The highest-conviction signal is Analogic Corp's $138.3 million TSA CT system delivery order, a competitive win in a growing airport security market with $499.7 million in potential value through 2033. The largest contract, START2 GROUP's $141.3 million BARDA biotechnology R&D award, carries high execution risk due to only $2.8 million outlayed and the company's small, foreign-owned status. A key risk is the upcoming August 2024 expiration of Leidos Biomedical Research's $121.5 million NIH contract, which may signal a re-compete or budget shift for NIAID vaccine research.

3 total filings
· daily

Contract Option Exercises — June 23, 2026

The three contracts totaling $401.1 million are heavily skewed toward civilian agencies (HHS and DHS), with only one-third defense-related, reflecting continued federal investment in health security and advanced airport screening technology. The highest-conviction signal is Analogic Corp's $138.3 million TSA delivery order for CT systems, a competitive win with a potential $499.7 billion ceiling that underscores durable demand for aviation security upgrades. Key risks include execution uncertainty on START2 Group's early-stage $141.3 million BARDA contract (only $2.8 million outlayed) and the pending August 2024 renewal of Leidos' $121.5 million NIH contract. Investors should monitor TSA budget cycles for Analogic's option exercises and START2 Group's milestone progress as critical catalysts.

3 total filings
· daily

All HHS Contracts — June 23, 2026

This digest covers two HHS contracts totaling $262.8 million, both civilian (non-defense) awards, with a dominant theme of federal health R&D spending. The highest-conviction signal is Leidos Biomedical Research’s $121.5 million cost-plus-fixed-fee delivery order from NIH/NCI, which provides stable, predictable margins through August 2024 but caps upside. The more speculative signal is START2 GROUP’s $141.3 million BARDA contract, which carries high execution risk due to only $2.8 million outlayed to date and the company’s small, foreign-owned status. Key risk: START2’s contract is early-stage and milestone-dependent, with potential for delays or protest vulnerability. Key watch item: Leidos’ contract renewal or follow-on award after August 2024, which will signal NIH budget continuity for vaccine research.

2 total filings
· daily

Mega Contracts Monitor ($100M+) — June 23, 2026

The three contracts totaling $401.1 million are overwhelmingly civilian, with two HHS awards and one DHS award; only the TSA contract for Analogic Corp carries a defense-adjacent security mission. The highest-conviction signal is Analogic Corp's $138.3 million delivery order for full-sized CT systems, which provides long-term revenue visibility through 2033 and reflects competitive strength in airport security technology. The largest contract by value, START2 GROUP, INC.'s $141.3 million BARDA award, carries high execution risk due to minimal outlays ($2.8M) and a small, foreign-owned contractor profile. A key risk is the impending expiration of Leidos Biomedical Research's $121.5 million NIH contract in August 2024, which creates a re-compete event that could affect Leidos' health R&D revenue stream.

3 total filings
· daily

High-Value Federal Grants ($5M+) — June 23, 2026

This digest covers $401.1 million in high-value federal obligations from June 23, 2026, with a 1:2 defense-to-civilian split. The dominant theme is advanced technology procurement for health/biodefense (HHS/BARDA and NIH) and homeland security (TSA). The highest-conviction signal is Analogic Corp's $138.3 million TSA CT system delivery order, which provides long-term revenue visibility through 2033 and signals competitive strength in airport security detection. A key risk is the START2 GROUP, INC. $141.3 million BARDA contract, where only $2.8 million has been outlayed, indicating early-stage execution risk and potential scalability concerns for a small, foreign-owned firm.

3 total filings
· daily

General Federal Contracts — June 23, 2026

The three contracts analyzed total $401.1 million in obligations, with a civilian-heavy split (2 of 3 from HHS, 1 from DHS) and no direct defense awards, though the DHS TSA contract supports national security infrastructure. The dominant sector theme is health and biodefense R&D, driven by BARDA and NIH funding, with a secondary theme in advanced airport security technology via TSA. The highest-conviction signal is the bullish $138.3 million Analogic Corp TSA CT systems delivery order, which offers long-term revenue visibility through 2033 and reflects competitive strength in a high-value security niche. A key risk is the $141.3 million START2 GROUP contract with BARDA, where only $2.8 million has been outlayed, signaling early-stage execution risk and potential milestone delays.

3 total filings
· daily

S&P 500 Technology Sector SEC Filings — June 23, 2026

The 22 filings from S&P 500 Technology constituents on June 23, 2026, reveal a sector defined by massive capital returns, significant insider profit-taking, and a governance overhang at Snowflake. Accenture's $7.5B buyback program and IBM's credit facility extension signal robust balance sheet strength and shareholder return commitments. However, a wave of insider selling, particularly the $119M sale by NVIDIA Director Mark Stevens and substantial sales by CrowdStrike's top executives, introduces a cautionary note, suggesting insiders are locking in gains amid elevated valuations. The period-over-period data, while not directly present in these specific filings, is reflected through the scale of capital deployment and insider actions. The key themes are capital allocation confidence versus insider valuation concerns, with Snowflake's proxy fight representing a distinct corporate governance risk. Investors should monitor these patterns for potential divergence between management actions and market sentiment.

20 high priority 2 medium 22 total filings
· daily

Nasdaq 100 Stocks SEC Filings — June 23, 2026

The six filings for June 23, 2026, all relate to NVIDIA Corporation, a core NASDAQ-100 constituent. The dominant theme is a coordinated wave of insider transactions, with five top executives (including CEO Jensen Huang and CFO Colette Kress) executing tax-withholding share disposals totaling ~$40.3M at $207.41, while Director Mark Stevens executed a large open-market sale of ~$119M at $210.44. This pattern of insider liquidity events, particularly the CEO's first significant disposal in months, creates a nuanced signal: the tax-withholding sales are routine, but Stevens' sale is a material bearish indicator. No period-over-period comparisons, forward-looking guidance, or capital allocation data were present in these filings, limiting trend analysis. The key takeaway is elevated insider selling pressure at a high stock price, warranting close monitoring for any follow-on sales or changes in corporate outlook.

6 high priority 6 total filings
· daily

US Activist Hedge Fund Institutional SEC 13D 13G — June 23, 2026

This batch of 43 filings reveals a concentrated period of activist and institutional activity on June 23, 2026, with several high-conviction themes emerging. A significant activist campaign is underway at **Equus Total Return (EQS)**, where a 5.6% holder publicly excoriated the board for a 65% NAV decline and excessive pay, demanding a strategic review. Concurrently, we see major insider monetization events: the CEO of **AST SpaceMobile** entered a $146.7M prepaid forward, and the CEO of **St. Joe Co** sold 622,200 shares. On the M&A front, **Apogee Therapeutics** agreed to a $135.11/share buyout by AbbVie, with activist holder Fairmount committing to support the deal. A notable pattern of institutional exit filings emerged, with **CDT Equity**, **CoreWeave**, and **Arqit Quantum** all seeing major holders reduce or eliminate stakes. The data also highlights a cluster of passive institutional positions in **Sleep Number Corp**, with both Jane Street and AQR Capital disclosing stakes exceeding 5%, suggesting a potential value play in the beaten-down retail sector. Overall, the filings paint a picture of significant capital rotation, with activists targeting underperformers for change and institutions adjusting positions ahead of a potential market inflection.

18 high priority 25 medium 43 total filings
· daily

S&P 500 Financials Sector SEC Filings — June 23, 2026

The five filings from S&P 500 Financials constituents reveal mixed insider sentiment with notable selling from AFLAC’s largest holder and Progressive’s CIO, while Mastercard’s director transaction is neutral. The sole operational filing is a Wells Fargo CMBS trust 8-K announcing a $475M multi-family/commercial mortgage securitization, signaling ongoing capital markets activity. No period-over-period comparisons or financial metrics are available from these filings, limiting trend analysis. Insider selling patterns in insurance (AFLAC, Progressive) warrant monitoring, but most trades are 10b5-1 pre-arranged. The CMBS issuance points to continued structured credit demand, potentially benefiting large banks. Overall, the filings suggest caution in insurance names and a steady but not explosive securitization environment.

4 high priority 1 medium 5 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — June 23, 2026

The sole filing from Conagra Brands within the Consumer Staples stream for this period is a routine, low-materiality 8-K regarding a director's decision not to stand for reelection. The departure of Emanuel 'Manny' Chirico is explicitly stated as not due to any disagreement, which removes a typical governance risk. The filing provides no period-over-period financial data, insider trading activity, capital allocation updates, or forward-looking guidance. Consequently, the digest is dominated by a single, neutral governance event. The primary actionable insight is the scheduled September 2026 Annual Meeting, which serves as a key date to monitor for any strategic shifts or further board changes. The lack of financial or operational data from this filing prevents any sector-wide trend analysis or comparison against other Consumer Staples peers.

1 high priority 1 total filings
· daily

S&P 500 Industrials Sector SEC Filings — June 23, 2026

This quiet session features only one filing from FedEx Corp., a transportation heavyweight in the S&P 500 Industrials. The standout development is the completion of the FedEx Freight spin-off on June 1, 2026, a transformative corporate action that unlocks significant value while loading FedEx Freight with $3.7B in debt. FedEx’s FY2026 results show strong top-line momentum (revenue up 12.6% YoY for Q4, 7.7% for the full year), but margin compression persists—GAAP operating margin fell 190 bps YoY in Q4, signaling cost pressures from the spin-off and elevated investments. Capital spending dropped to a record-low 4.0% of revenue, reflecting capital discipline, but insider selling by a key executive raises caution. Forward guidance points to ~11% revenue growth in calendar 2026, but adjusted EPS estimates ($16.90-$18.10) imply a tepid profit recovery. The key portfolio-level takeaway: Industrial companies are aggressively restructuring (spin-offs, cost-cutting) but facing headwinds in margin expansion.

1 medium 1 total filings
· daily

S&P 500 Energy Sector SEC Filings — June 23, 2026

The single filing from ConocoPhillips today (an 8-K) is a low-materiality personnel announcement, providing no financial data for period-over-period comparisons, insider transactions, or forward-looking guidance. The retirement of General Counsel Kelly B. Rose, effective September 1, 2026, is a routine succession event with no immediate market impact. Without revenue, margin, or capital allocation data from this filing, no sector-wide themes or portfolio-level trends can be derived. The digest is therefore limited to a single governance-related watch item. No other S&P 500 Energy constituents filed today, resulting in an absence of actionable investment signals, risk flags, or opportunities from this batch.

1 high priority 1 total filings